Exclusive

Publication

Byline

Location

Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, March 30 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... Read More


Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, March 30 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... Read More


Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, March 30 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... Read More


Singapore Clinical Trial: EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Singapore, March 30 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate... Read More


Singapore Company Announcement: LION GLOBAL INVESTORS LIMITED

Singapore, March 30 -- LION GLOBAL INVESTORS LIMITED made the following announcement: Security Name: LION-PHILLIP S-REIT ETF General Announcement::Net Tangible Assets ("NTA") per unit (https://links... Read More


Singapore Company Announcement: CIMB BANK BERHAD

Singapore, March 30 -- CIMB BANK BERHAD made the following announcement: Security Name: NA Financial Statements and Related Announcement::Full Yearly Results (https://links.sgx.com/1.0.0/corporate-a... Read More


Singapore Company Announcement: CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD.

Singapore, March 30 -- CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD. made the following announcement: Security Name: MULTIPLE General Announcement::NET ASSET VALUE ("NAV") PER UNIT (https://links... Read More


Singapore Company Announcement: CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD.

Singapore, March 30 -- CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD. made the following announcement: Security Name: MULTIPLE General Announcement::NET ASSET VALUE ("NAV") PER UNIT (https://links... Read More


Singapore Company Announcement: KOOKMIN BANK

Singapore, March 30 -- KOOKMIN BANK made the following announcement: Security Name: KOOKMINBK USD50MF270324 Debt - Listing Confirmation::USD 50,000,000 FLOATING RATE NOTES DUE MARCH 2027 (https://li... Read More


Singapore Company Announcement: CONNECTICUT AVENUE SECURITIES TRUST 2026-R02

Singapore, March 30 -- CONNECTICUT AVENUE SECURITIES TRUST 2026-R02 made the following announcement: Security Name: MULTIPLE Debt - Listing Confirmation::Listing Confirmation (https://links.sgx.com/... Read More